Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435685 | 0.83 | KMT2A (0.49) | PTPN1LMNAHPGDSMN1; SMN2RAB9A | |
| SCHEMBL5015209 | 0.79 | LMNA (0.40) | PTPN1LMNARAB9AGAAENPP2 | |
| SCHEMBL5013951 | 0.74 | ENPP2 (0.46) | GAAENPP2DGAT2POLBMEN1 | |
| SCHEMBL5495326 | 0.71 | CA1 (0.59) | LMNAPOLBMEN1KMT2AMAPT | |
| SCHEMBL1356115 | 0.71 | KMT2A (0.50) | PTPN1LMNAHPGDRAB9AGAA | |
| SCHEMBL6934094 | 0.71 | GAA (0.61) | HPGDSMN1; SMN2RAB9AGAAPOLB | |
| SCHEMBL7800005 | 0.71 | NPC1 (0.63) | LMNAHPGDSMN1; SMN2RAB9APOLB | |
| SCHEMBL23521940 | 0.68 | CYP1A1 (0.70) | SMN1; SMN2POLBMEN1KMT2AMAPT | |
| SCHEMBL7833686 | 0.68 | TP53 (0.72) | LMNAHPGDSMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1848123 | 0.68 | ENPP2 (0.43) | PTPN1LMNAHPGDSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115720-B2 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | claimed |
| US-20040096393-A1 | Therapeutic and diagnostic compounds, compositions, and methods | PONIARD PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1390081-A2 | THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS | NEORX CORPORATION (US) | 2004-02-25 | — | — | EP | claimed |
| WO-2002062398-A2 | RADIOACTIVELY LABELLED CONJUGATES OF PHOSPHONATES | NEORX CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| US-7385042-B2 | Therapeutic and diagnostic compounds, compositions, and methods | PONIARD PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060251578-A1 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | NEORX CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7115720-B2 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040096393-A1 | Therapeutic and diagnostic compounds, compositions, and methods | PONIARD PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1390081-A2 | THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS | NEORX CORPORATION (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002062398-A2 | RADIOACTIVELY LABELLED CONJUGATES OF PHOSPHONATES | NEORX CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251578-A1 | Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) | PHOSPHO1, SNRPA1, NPM1 | PTPN1 83/4885LMNA 2557/4885HPGD 2060/4885 |
| US-20040096393-A1 | Therapeutic and diagnostic compounds, compositions, and methods | SLC10A1, MEN1, REN | PTPN1 2122/4885LMNA 1040/4885HPGD 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.